Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers

Table 2 Score to evaluate the benefits of the treatment with chemo-immunotherapy in dogs with DLBCL and MZL

Serum LDH levels		Normal (0)			Increased (+ 1)
Stage		III/IV (0)			V (+ 1)
Substage		b (0)			a (+ 1)
Steroids before referral		Yes (0)			No (+ 1)
Dogs with diffuse large B-cell lymphoma
Score	Median LSS			1-year SR		2-year SR		3-year SR
Score	CH	CH-IM	P	CH	CH-IM	CH	CH-IM	CH	CH-IM
4 (n = 27)	85	480	< 0.001*	0%	57%	0%	15%	0%	0%
2–3 (n = 99)	190	435	0.030*	23%	50%	12%	18%	8%	11%
0–1 (n = 22)	286	374	0.573	40%	45%	40%	27%	25%	11%
All cases (n = 148)	165	413	0.001*	20%	51%	13%	19%	8%	10%
Dogs with marginal zone lymphoma
Score	Median LSS			1-year SR		2-year SR		3-year SR
Score	CH	CH-IM	P	CH	CH-IM	CH	CH-IM	CH	CH-IM
3–4 (n = 29)	160	680	< 0.001*	9%	77%	0%	36%	0%	12%
0–2 (n = 20)	560	172	0.165	56%	14%	38%	14%	25%	0%
All cases (n = 49)	254	399	0.245	30%	55%	16%	28%	10%	10%

Abbreviations: LDH, lactate dehydrogenase; LSS, lymphoma specific survival; SR, survival rate; CH, chemotherapy; CH-IM, chemo-immunotherapy
* Significant